Bruker BioSpin

The world’s most comprehensive range of magnetic resonance and preclinical imaging instrumentation available under one brand - a brand synonymous with excellence, innovation and quality. Bruker is offering a wide range of applications for molecular characterization in chemistry and life sciences as well as solutions for materials and preclinical research. The Bruker BioSpin business group includes NMR, EPR, compact and Time-Domain (TD) NMR, preclinical MRI, optical imaging, microCT, and PET/SPECT/CT.a

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

EMMAUS LIFE SCIENCES ANNOUNCES LAUNCH OF FULL-SERVICE TELEHEALTH SOLUTION

Emmaus Life Sciences, Inc. | April 12, 2022

news image

Emmaus Life Sciences, Inc. (OTQXC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the launch of an innovative full-service telehealth solution with its strategic partners, including Asembia LLC, US Bioservices Corporation and UpScriptHealth. The telehealth program capitalizes on the expansion of telemedicine in the U.S. to afford patients and providers on-line access to Endari®, the company's prescription-grade L-gl...

Read More

RESEARCH

POSTERA ANNOUNCES $260M MULTI-TARGET STRATEGIC AI LAB COLLABORATION WITH PFIZER

PostEra | January 12, 2022

news image

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's da...

Read More

INDUSTRIAL IMPACT

AXION BIOSYSTEMS EXPANDS OPERATIONS WITH ACQUISITION OF M-SOLV MANUFACTURING LIMITED

Axion BioSystems | February 03, 2022

news image

Axion BioSystems, a leading life sciences tools company focused on advanced bioelectronic assay technologies, announces the acquisition of UK-based printed electronics manufacturer M-Solv Manufacturing Limited, a subsidiary of M-Solv Ltd. The creation of the new division, called Axion BioSystems Manufacturing, UK, Ltd., cements the six-year partnership between the companies and positions Axion for continued growth and innovation. “The need to control th...

Read More

MEDTECH

CELLCARTA EXPANDS ITS BIOMARKER CAPABILITIES FOR CLINICAL TRIALS BY ADDING OLINK TECHNOLOGY TO ITS GLOBAL SERVICES

CellCarta | September 01, 2021

news image

CellCarta and Olink Proteomics AB announced today a strategic collaboration to offer Olink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies. CellCarta is a global leader in precision medicine and with more than 20 years of experience in mass spectrometry the company continues to invest in the field of proteomic biomarkers to better understand diseases and support therapeutic development ...

Read More
news image

MEDICAL

EMMAUS LIFE SCIENCES ANNOUNCES LAUNCH OF FULL-SERVICE TELEHEALTH SOLUTION

Emmaus Life Sciences, Inc. | April 12, 2022

Emmaus Life Sciences, Inc. (OTQXC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the launch of an innovative full-service telehealth solution with its strategic partners, including Asembia LLC, US Bioservices Corporation and UpScriptHealth. The telehealth program capitalizes on the expansion of telemedicine in the U.S. to afford patients and providers on-line access to Endari®, the company's prescription-grade L-gl...

Read More
news image

RESEARCH

POSTERA ANNOUNCES $260M MULTI-TARGET STRATEGIC AI LAB COLLABORATION WITH PFIZER

PostEra | January 12, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's da...

Read More
news image

INDUSTRIAL IMPACT

AXION BIOSYSTEMS EXPANDS OPERATIONS WITH ACQUISITION OF M-SOLV MANUFACTURING LIMITED

Axion BioSystems | February 03, 2022

Axion BioSystems, a leading life sciences tools company focused on advanced bioelectronic assay technologies, announces the acquisition of UK-based printed electronics manufacturer M-Solv Manufacturing Limited, a subsidiary of M-Solv Ltd. The creation of the new division, called Axion BioSystems Manufacturing, UK, Ltd., cements the six-year partnership between the companies and positions Axion for continued growth and innovation. “The need to control th...

Read More
news image

MEDTECH

CELLCARTA EXPANDS ITS BIOMARKER CAPABILITIES FOR CLINICAL TRIALS BY ADDING OLINK TECHNOLOGY TO ITS GLOBAL SERVICES

CellCarta | September 01, 2021

CellCarta and Olink Proteomics AB announced today a strategic collaboration to offer Olink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies. CellCarta is a global leader in precision medicine and with more than 20 years of experience in mass spectrometry the company continues to invest in the field of proteomic biomarkers to better understand diseases and support therapeutic development ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us